During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is ...

To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent years defined the company. “We always call ourselves a neuroscience company ...

Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results , with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several ...

Shares of Biogen dipped after the biotechnology company said it expects to report a roughly $222 million pretax charge in the fourth quarter. Shares were down 5.9% to $167.88 on Wednesday morning. The ...

Drug companies Merck and Allergan have expressed interest in taking over biotechnology giant Biogen, The Wall Street Journal reports. People familiar with the matter told the publication that Merck ...

Wall Street Zen upgraded shares of Biogen (NASDAQ:BIIB – Free Report) from a buy rating to a strong-buy rating in a report released on Sunday morning. Several other research analysts have also ...